The Chemours Company (CC): Can High Growth Still Justify Its December Share Price? – Simply Wall St

Posted December 7, 2017 5:28 am by Category: WARREN BUFFETT WATCH Tags: ,


The Lincolnian Online

The Chemours Company (CC): Can High Growth Still Justify Its December Share Price?
Simply Wall St
As Warren Buffett's right-hand man Charlie Munger said, “No matter how wonderful a business is, it's not worth an infinite price.” Chemours is available at price-to-earnings ratio of 33.12x, showing us it is overvalued compared to the US market average
Zacks' 7 Best Strong Buys for 2018Zacks.com
SEC FORM 4 – SEC.govSEC.gov
SEC FORM 4 – SEC.govSEC.gov

all 57 news articles »